| Autor: |
Karasek, Petr, Skacel, Tomas, Kocakova, Ilona, Bednarik, Otakar, Petruzelka, Lubos, Melichar, Bohuslav, Bustova, Ivana, Spurny, Vladimir, Trason, Tomas |
| Zdroj: |
Expert Opinion on Pharmacotherapy; April 2003, Vol. 4 Issue: 4 p581-586, 6p |
| Abstrakt: |
Pancreatic cancer has one of the worst prognosis of any malignant disease. Systemic therapy is often administered because the disease is usually detected at advanced stages. Gemcitabine (Gemzar™, Eli Lilly & Co.) has proven activity in the treatment of pancreatic cancer. Gemcitabine 1000 mg/m2 was given on days 1, 8 and 15, every 4 weeks. A total of 100 chemonaive patients with locally advanced or metastatic pancreatic cancer were enrolled; 32 and 68% had stage III and IV disease, respectively. The average number of administered cycles was 3.5 (range: 1 – 12). The overall response rate was 13%, with 13 partial responders. The median time to progression was 13.5 weeks (range: 3 – 56; 95% CI = 12 – 14). The median survival was 32 weeks (range: 4 – 104; 95% CI = 27 – 36). Clinical benefit response was acheived for 26 patients (26%). Grade 3/4 haematological toxicities occurred infrequently (anaemia: 5%; neutropenia: 8% and thrombocytopenia: 3% of patients). Grade 3/4 non-haematological toxicities were not observed. There were no treatment-related deaths. Gemcitabine treatment of patients with locally advanced or metastatic pancreatic cancer is effective and well-tolerated. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
